Johnson & Johnson (NYSE:JNJ) Shares Up 0.8%

Johnson & Johnson (NYSE:JNJ - Get Free Report) shares traded up 0.8% during mid-day trading on Monday . The company traded as high as $149.35 and last traded at $149.15. 2,175,283 shares changed hands during mid-day trading, a decline of 70% from the average session volume of 7,218,512 shares. The stock had previously closed at $147.91.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Raymond James upped their target price on Johnson & Johnson from $172.00 to $175.00 and gave the company an "outperform" rating in a research report on Wednesday, January 3rd. StockNews.com raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, February 6th. HSBC raised Johnson & Johnson from a "hold" rating to a "buy" rating and upped their target price for the company from $169.00 to $170.00 in a research report on Thursday. Bank of America cut their target price on Johnson & Johnson from $180.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 17th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Monday, April 15th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus price target of $175.86.

Johnson & Johnson Stock Performance

The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. The firm has a market cap of $359.35 billion, a price-to-earnings ratio of 9.30, a price-to-earnings-growth ratio of 2.44 and a beta of 0.53. The stock has a fifty day moving average price of $156.15 and a 200 day moving average price of $155.63.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating analysts' consensus estimates of $2.64 by $0.07. The business had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a return on equity of 36.43% and a net margin of 45.26%. The firm's revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.68 EPS. As a group, analysts predict that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.33%. The ex-dividend date is Monday, May 20th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.19. Johnson & Johnson's dividend payout ratio (DPR) is 29.68%.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 59,397 shares of the firm's stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the firm's stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder & Johnson Johnson sold 3,725 shares of the firm's stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now owns 4,099,575 shares of the company's stock, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Oakworth Capital Inc. boosted its position in shares of Johnson & Johnson by 10.8% in the 1st quarter. Oakworth Capital Inc. now owns 21,780 shares of the company's stock worth $3,445,000 after purchasing an additional 2,130 shares during the last quarter. Drive Wealth Management LLC grew its stake in Johnson & Johnson by 4.5% in the first quarter. Drive Wealth Management LLC now owns 9,625 shares of the company's stock valued at $1,523,000 after acquiring an additional 414 shares during the period. Outlook Wealth Advisors LLC grew its stake in Johnson & Johnson by 2.9% in the first quarter. Outlook Wealth Advisors LLC now owns 12,628 shares of the company's stock valued at $1,998,000 after acquiring an additional 353 shares during the period. Donaldson Capital Management LLC grew its stake in Johnson & Johnson by 3.0% in the first quarter. Donaldson Capital Management LLC now owns 338,853 shares of the company's stock valued at $53,603,000 after acquiring an additional 10,006 shares during the period. Finally, Raymond James & Associates grew its stake in Johnson & Johnson by 5.3% in the first quarter. Raymond James & Associates now owns 6,384,341 shares of the company's stock valued at $1,009,939,000 after acquiring an additional 322,634 shares during the period. 69.55% of the stock is currently owned by institutional investors.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.